Short answer
Zimmer Biomet (ZBH) filed an 8-K current report with the SEC on September 8, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Group President Kevin Thornal departing September 30, 2026 following restructuring of his position.
Zimmer Biomet 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Group President Kevin Thornal departing September 30, 2026 following restructuring of his position
- Leadership transition affects Global Businesses and Americas operations
- Eligible for severance equal to 12 months’ base salary plus target bonus and 12 months’ COBRA premiums
- Severance contingent on executing and not revoking a general release favoring Zimmer Biomet
Item EX-99.1 · Exhibit EX-99.1
- Effective October 1, Gary Campbell becomes President, Americas, leading commercial strategy across the United States, Canada and Latin America
- Brian Hatcher expands to global portfolio leadership, adding Knees and Hips to Recon, S.E.T., CMFT, Neuro and Biosurgery
- Bradley Kessler will lead Americas robotics, technology and data commercialization ahead of the Monogram robot launch expected in 2027
- Kevin Thornal departs September 30 after transition period, creating a senior leadership succession change
- 2026 financial outlook reiterated, while restructuring targets greater commercial focus and growth into 2027 and beyond
Other items in this filing:
- Item 7.01: Regulation FD Disclosure
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Zimmer Biomet 8-K filings
Get the next ZBH 8-K as it lands
Follow ZBH for push alerts, or ask the research agent what this filing means.